These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 33507825)

  • 41. Potential savings associated with drug substitution in Medicare Part D: the Translating Research into Action for Diabetes (TRIAD) study.
    Duru OK; Ettner SL; Turk N; Mangione CM; Brown AF; Fu J; Simien L; Tseng CW
    J Gen Intern Med; 2014 Jan; 29(1):230-6. PubMed ID: 23975059
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Burden of chronic obstructive pulmonary disease in Medicare beneficiaries residing in long-term care facilities.
    Simoni-Wastila L; Blanchette CM; Qian J; Yang HW; Zhao L; Zuckerman IH; Pak GH; Silver H; Dalal AA
    Am J Geriatr Pharmacother; 2009 Oct; 7(5):262-70. PubMed ID: 19948302
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Brand versus generic alendronate: gastrointestinal effects measured by resource utilization.
    Halkin H; Dushenat M; Silverman B; Shalev V; Loebstein R; Lomnicky Y; Friedman N
    Ann Pharmacother; 2007 Jan; 41(1):29-34. PubMed ID: 17190847
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Medicaid prescription limits: policy trends and comparative impact on utilization.
    Lieberman DA; Polinski JM; Choudhry NK; Avorn J; Fischer MA
    BMC Health Serv Res; 2016 Jan; 16():15. PubMed ID: 26772962
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Factors influencing the use of the "not for generic substitution" mention for prescriptions in primary care: a survey with general practitioners.
    Beauvais V; Marque A; Ferté G; Chrusciel J; Souille J; Nazeyrollas P; Sanchez S
    BMC Health Serv Res; 2018 Nov; 18(1):850. PubMed ID: 30419890
    [TBL] [Abstract][Full Text] [Related]  

  • 46. State Laws and Generic Substitution in the Year After New Generic Competition.
    Rome BN; Sarpatwari A; Kesselheim AS
    Value Health; 2022 Oct; 25(10):1736-1742. PubMed ID: 35487821
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Generic medications for you, but brand-name medications for me.
    Keenum AJ; Devoe JE; Chisolm DJ; Wallace LS
    Res Social Adm Pharm; 2012; 8(6):574-8. PubMed ID: 22357268
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impact of Medicaid prescription copayments on use of antipsychotics and other medications in patients with schizophrenia.
    Doshi JA; Li P; Desai S; Marcus SC
    J Med Econ; 2017 Dec; 20(12):1252-1260. PubMed ID: 28792299
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Fragmented ambulatory care and subsequent emergency department visits and hospital admissions among Medicaid beneficiaries.
    Kern LM; Seirup JK; Rajan M; Jawahar R; Stuard SS
    Am J Manag Care; 2019 Mar; 25(3):107-112. PubMed ID: 30875178
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Resource utilization and costs of schizophrenia patients treated with olanzapine versus quetiapine in a Medicaid population.
    Yu AP; Atanasov P; Ben-Hamadi R; Birnbaum H; Stensland MD; Philips G
    Value Health; 2009; 12(5):708-15. PubMed ID: 19508658
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Medicare Spending on Brand-name Combination Medications vs Their Generic Constituents.
    Sacks CA; Lee CC; Kesselheim AS; Avorn J
    JAMA; 2018 Aug; 320(7):650-656. PubMed ID: 30140875
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Impact of cost sharing on prescription drugs used by Medicare beneficiaries.
    Goedken AM; Urmie JM; Farris KB; Doucette WR
    Res Social Adm Pharm; 2010 Jun; 6(2):100-9. PubMed ID: 20511109
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Effect of Florida Medicaid's State-Mandated Formulary Provision on Prescription Drug Use and Health Plan Costs in a Medicaid Managed Care Plan.
    Munshi KD; Mager D; Ward KM; Mischel B; Henderson RR
    J Manag Care Spec Pharm; 2018 Feb; 24(2):124-131. PubMed ID: 29384030
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evaluation of Switch-to-Brand Rates as a Potential Signal for Therapeutic Equivalency of Generic Antidepressants: A Real-World Retrospective Cohort Study.
    Kalaria S; Spence O; Hong K; dosReis S; Gopalakrishnan M
    Clin Pharmacol Ther; 2021 Aug; 110(2):443-451. PubMed ID: 33811324
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Trends in the utilization of, spending on, and prices for outpatient antifungal agents in US Medicaid programs: 1991-2009.
    Desai VC; Cavanaugh TM; Kelton CM; Guo JJ; Heaton PC
    Clin Ther; 2012 Oct; 34(10):2118-2131.e1. PubMed ID: 23031625
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of hospitalizations, emergency department visits, and costs in a historical cohort of Texas Medicaid patients with chronic obstructive pulmonary disease, by initial medication regimen.
    Rascati KL; Akazawa M; Johnsrud M; Stanford RH; Blanchette CM
    Clin Ther; 2007 Jun; 29(6):1203-13. PubMed ID: 17692734
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Adherence with brand versus generic bisphosphonates among osteoporosis patients: a new-user cohort study in the French National Healthcare Insurance database.
    Viprey M; Xue Y; Rousseau A; Payet C; Chapurlat R; Caillet P; Dima A; Schott AM
    Sci Rep; 2020 May; 10(1):7446. PubMed ID: 32366863
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Increased olanzapine discontinuation and health care resource utilization following a Medicaid policy change.
    Signorovitch J; Birnbaum H; Ben-Hamadi R; Yu AP; Kidolezi Y; Kelley D; Phillips G; Lawson A; Ball DE
    J Clin Psychiatry; 2011 Jun; 72(6):787-94. PubMed ID: 21294993
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Does substitution of brand name medications by generics differ between pharmacotherapeutic classes? A population-based cohort study in France.
    Molinier A; Palmaro A; Rousseau V; Sommet A; Bourrel R; Montastruc JL; Bagheri H
    Eur J Clin Pharmacol; 2017 Apr; 73(4):471-477. PubMed ID: 28035437
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prostaglandin Coverage and Costs to Medicare and Medicare Beneficiaries, 2009-2017.
    Bartlett VL; Liu P; Dhruva SS; Shah ND; Bollinger KE; Ross JS
    J Manag Care Spec Pharm; 2020 Apr; 26(4):562-567. PubMed ID: 32223594
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.